TrialKidney international2011

A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.

Howard Trachtman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.